Histidine metabolism drives liver cancer progression via immune microenvironment modulation through metabolic reprogramming
Histidine metabolism is crucial in role in tumor biology, contributing to tumor progression, immune regulation, and metabolic reprogramming. In hepatocellular carcinoma (HCC), dysregulated histidine metabolism may promote tumor growth and immune evasion, although the specific mechanisms remain poorl...
Saved in:
| Published in | Journal of translational medicine Vol. 23; no. 1; pp. 262 - 20 |
|---|---|
| Main Authors | , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
BioMed Central Ltd
04.03.2025
BioMed Central BMC |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Histidine metabolism is crucial in role in tumor biology, contributing to tumor progression, immune regulation, and metabolic reprogramming. In hepatocellular carcinoma (HCC), dysregulated histidine metabolism may promote tumor growth and immune evasion, although the specific mechanisms remain poorly understood.
Using single-cell RNA sequencing, the expression patterns of histidine metabolism-related genes were evaluated across different cell types in HCC samples. In vivo and in vitro experiments were conducted to validate how histidine treatment affects macrophage and T-cell function. Furthermore, the TCGA database was utilized to construct a prognostic model to identify the key gene BUD23 and to examine its correlation with metabolism and immune infiltration.
The proportion of parenchymal cells exhibiting high histidine metabolism was significantly increased, accompanied by a general reduction in immune and stromal cell infiltration. Notably, macrophages and T cells demonstrated impaired antitumor functions. In the high histidine metabolism group, multiple critical cell communication pathways (e.g., MIF, CLEC, MHC II) were downregulated, macrophages shifted toward immunosuppressive subpopulations, T cells exhibited an exhaustion phenotype, and CD8 + T-cell activation was diminished. Further in vivo and in vitro co-culture experiments confirmed that elevated histidine concentrations promoted M2 polarization in macrophages and weakened T-cell cytotoxicity, accelerating tumor proliferation. According to TCGA analyses, BUD23 was upregulated in the high histidine metabolism group and significantly negatively correlated with patient survival and immune cell infiltration. Silencing BUD23 boosted immune cell activation and cytotoxic effects, effectively reversing the immunosuppressive microenvironment. A multivariable Cox regression-based prognostic model indicated unfavorable outcomes in patients with high histidine metabolism.
Histidine metabolism drives tumor cell metabolic reprogramming and reshapes the tumor immune microenvironment through intercellular communication, thereby promoting tumor progression. BUD23 shows promise as a biomarker for prognosis and immune response prediction in liver cancer. This study provides new therapeutic targets and theoretical support for liver cancer treatment by targeting histidine metabolism. |
|---|---|
| AbstractList | Background Histidine metabolism is crucial in role in tumor biology, contributing to tumor progression, immune regulation, and metabolic reprogramming. In hepatocellular carcinoma (HCC), dysregulated histidine metabolism may promote tumor growth and immune evasion, although the specific mechanisms remain poorly understood. Methods Using single-cell RNA sequencing, the expression patterns of histidine metabolism-related genes were evaluated across different cell types in HCC samples. In vivo and in vitro experiments were conducted to validate how histidine treatment affects macrophage and T-cell function. Furthermore, the TCGA database was utilized to construct a prognostic model to identify the key gene BUD23 and to examine its correlation with metabolism and immune infiltration. Results The proportion of parenchymal cells exhibiting high histidine metabolism was significantly increased, accompanied by a general reduction in immune and stromal cell infiltration. Notably, macrophages and T cells demonstrated impaired antitumor functions. In the high histidine metabolism group, multiple critical cell communication pathways (e.g., MIF, CLEC, MHC II) were downregulated, macrophages shifted toward immunosuppressive subpopulations, T cells exhibited an exhaustion phenotype, and CD8 + T-cell activation was diminished. Further in vivo and in vitro co-culture experiments confirmed that elevated histidine concentrations promoted M2 polarization in macrophages and weakened T-cell cytotoxicity, accelerating tumor proliferation. According to TCGA analyses, BUD23 was upregulated in the high histidine metabolism group and significantly negatively correlated with patient survival and immune cell infiltration. Silencing BUD23 boosted immune cell activation and cytotoxic effects, effectively reversing the immunosuppressive microenvironment. A multivariable Cox regression-based prognostic model indicated unfavorable outcomes in patients with high histidine metabolism. Conclusion Histidine metabolism drives tumor cell metabolic reprogramming and reshapes the tumor immune microenvironment through intercellular communication, thereby promoting tumor progression. BUD23 shows promise as a biomarker for prognosis and immune response prediction in liver cancer. This study provides new therapeutic targets and theoretical support for liver cancer treatment by targeting histidine metabolism. Keywords: Histidine metabolism, Hepatocellular carcinoma, Tumor microenvironment, Immune suppression, BUD23, Prognosis Histidine metabolism is crucial in role in tumor biology, contributing to tumor progression, immune regulation, and metabolic reprogramming. In hepatocellular carcinoma (HCC), dysregulated histidine metabolism may promote tumor growth and immune evasion, although the specific mechanisms remain poorly understood.BACKGROUNDHistidine metabolism is crucial in role in tumor biology, contributing to tumor progression, immune regulation, and metabolic reprogramming. In hepatocellular carcinoma (HCC), dysregulated histidine metabolism may promote tumor growth and immune evasion, although the specific mechanisms remain poorly understood.Using single-cell RNA sequencing, the expression patterns of histidine metabolism-related genes were evaluated across different cell types in HCC samples. In vivo and in vitro experiments were conducted to validate how histidine treatment affects macrophage and T-cell function. Furthermore, the TCGA database was utilized to construct a prognostic model to identify the key gene BUD23 and to examine its correlation with metabolism and immune infiltration.METHODSUsing single-cell RNA sequencing, the expression patterns of histidine metabolism-related genes were evaluated across different cell types in HCC samples. In vivo and in vitro experiments were conducted to validate how histidine treatment affects macrophage and T-cell function. Furthermore, the TCGA database was utilized to construct a prognostic model to identify the key gene BUD23 and to examine its correlation with metabolism and immune infiltration.The proportion of parenchymal cells exhibiting high histidine metabolism was significantly increased, accompanied by a general reduction in immune and stromal cell infiltration. Notably, macrophages and T cells demonstrated impaired antitumor functions. In the high histidine metabolism group, multiple critical cell communication pathways (e.g., MIF, CLEC, MHC II) were downregulated, macrophages shifted toward immunosuppressive subpopulations, T cells exhibited an exhaustion phenotype, and CD8 + T-cell activation was diminished. Further in vivo and in vitro co-culture experiments confirmed that elevated histidine concentrations promoted M2 polarization in macrophages and weakened T-cell cytotoxicity, accelerating tumor proliferation. According to TCGA analyses, BUD23 was upregulated in the high histidine metabolism group and significantly negatively correlated with patient survival and immune cell infiltration. Silencing BUD23 boosted immune cell activation and cytotoxic effects, effectively reversing the immunosuppressive microenvironment. A multivariable Cox regression-based prognostic model indicated unfavorable outcomes in patients with high histidine metabolism.RESULTSThe proportion of parenchymal cells exhibiting high histidine metabolism was significantly increased, accompanied by a general reduction in immune and stromal cell infiltration. Notably, macrophages and T cells demonstrated impaired antitumor functions. In the high histidine metabolism group, multiple critical cell communication pathways (e.g., MIF, CLEC, MHC II) were downregulated, macrophages shifted toward immunosuppressive subpopulations, T cells exhibited an exhaustion phenotype, and CD8 + T-cell activation was diminished. Further in vivo and in vitro co-culture experiments confirmed that elevated histidine concentrations promoted M2 polarization in macrophages and weakened T-cell cytotoxicity, accelerating tumor proliferation. According to TCGA analyses, BUD23 was upregulated in the high histidine metabolism group and significantly negatively correlated with patient survival and immune cell infiltration. Silencing BUD23 boosted immune cell activation and cytotoxic effects, effectively reversing the immunosuppressive microenvironment. A multivariable Cox regression-based prognostic model indicated unfavorable outcomes in patients with high histidine metabolism.Histidine metabolism drives tumor cell metabolic reprogramming and reshapes the tumor immune microenvironment through intercellular communication, thereby promoting tumor progression. BUD23 shows promise as a biomarker for prognosis and immune response prediction in liver cancer. This study provides new therapeutic targets and theoretical support for liver cancer treatment by targeting histidine metabolism.CONCLUSIONHistidine metabolism drives tumor cell metabolic reprogramming and reshapes the tumor immune microenvironment through intercellular communication, thereby promoting tumor progression. BUD23 shows promise as a biomarker for prognosis and immune response prediction in liver cancer. This study provides new therapeutic targets and theoretical support for liver cancer treatment by targeting histidine metabolism. Abstract Background Histidine metabolism is crucial in role in tumor biology, contributing to tumor progression, immune regulation, and metabolic reprogramming. In hepatocellular carcinoma (HCC), dysregulated histidine metabolism may promote tumor growth and immune evasion, although the specific mechanisms remain poorly understood. Methods Using single-cell RNA sequencing, the expression patterns of histidine metabolism–related genes were evaluated across different cell types in HCC samples. In vivo and in vitro experiments were conducted to validate how histidine treatment affects macrophage and T-cell function. Furthermore, the TCGA database was utilized to construct a prognostic model to identify the key gene BUD23 and to examine its correlation with metabolism and immune infiltration. Results The proportion of parenchymal cells exhibiting high histidine metabolism was significantly increased, accompanied by a general reduction in immune and stromal cell infiltration. Notably, macrophages and T cells demonstrated impaired antitumor functions. In the high histidine metabolism group, multiple critical cell communication pathways (e.g., MIF, CLEC, MHC II) were downregulated, macrophages shifted toward immunosuppressive subpopulations, T cells exhibited an exhaustion phenotype, and CD8 + T-cell activation was diminished. Further in vivo and in vitro co-culture experiments confirmed that elevated histidine concentrations promoted M2 polarization in macrophages and weakened T-cell cytotoxicity, accelerating tumor proliferation. According to TCGA analyses, BUD23 was upregulated in the high histidine metabolism group and significantly negatively correlated with patient survival and immune cell infiltration. Silencing BUD23 boosted immune cell activation and cytotoxic effects, effectively reversing the immunosuppressive microenvironment. A multivariable Cox regression–based prognostic model indicated unfavorable outcomes in patients with high histidine metabolism. Conclusion Histidine metabolism drives tumor cell metabolic reprogramming and reshapes the tumor immune microenvironment through intercellular communication, thereby promoting tumor progression. BUD23 shows promise as a biomarker for prognosis and immune response prediction in liver cancer. This study provides new therapeutic targets and theoretical support for liver cancer treatment by targeting histidine metabolism. Histidine metabolism is crucial in role in tumor biology, contributing to tumor progression, immune regulation, and metabolic reprogramming. In hepatocellular carcinoma (HCC), dysregulated histidine metabolism may promote tumor growth and immune evasion, although the specific mechanisms remain poorly understood. Using single-cell RNA sequencing, the expression patterns of histidine metabolism-related genes were evaluated across different cell types in HCC samples. In vivo and in vitro experiments were conducted to validate how histidine treatment affects macrophage and T-cell function. Furthermore, the TCGA database was utilized to construct a prognostic model to identify the key gene BUD23 and to examine its correlation with metabolism and immune infiltration. The proportion of parenchymal cells exhibiting high histidine metabolism was significantly increased, accompanied by a general reduction in immune and stromal cell infiltration. Notably, macrophages and T cells demonstrated impaired antitumor functions. In the high histidine metabolism group, multiple critical cell communication pathways (e.g., MIF, CLEC, MHC II) were downregulated, macrophages shifted toward immunosuppressive subpopulations, T cells exhibited an exhaustion phenotype, and CD8 + T-cell activation was diminished. Further in vivo and in vitro co-culture experiments confirmed that elevated histidine concentrations promoted M2 polarization in macrophages and weakened T-cell cytotoxicity, accelerating tumor proliferation. According to TCGA analyses, BUD23 was upregulated in the high histidine metabolism group and significantly negatively correlated with patient survival and immune cell infiltration. Silencing BUD23 boosted immune cell activation and cytotoxic effects, effectively reversing the immunosuppressive microenvironment. A multivariable Cox regression-based prognostic model indicated unfavorable outcomes in patients with high histidine metabolism. Histidine metabolism drives tumor cell metabolic reprogramming and reshapes the tumor immune microenvironment through intercellular communication, thereby promoting tumor progression. BUD23 shows promise as a biomarker for prognosis and immune response prediction in liver cancer. This study provides new therapeutic targets and theoretical support for liver cancer treatment by targeting histidine metabolism. Histidine metabolism is crucial in role in tumor biology, contributing to tumor progression, immune regulation, and metabolic reprogramming. In hepatocellular carcinoma (HCC), dysregulated histidine metabolism may promote tumor growth and immune evasion, although the specific mechanisms remain poorly understood. Using single-cell RNA sequencing, the expression patterns of histidine metabolism-related genes were evaluated across different cell types in HCC samples. In vivo and in vitro experiments were conducted to validate how histidine treatment affects macrophage and T-cell function. Furthermore, the TCGA database was utilized to construct a prognostic model to identify the key gene BUD23 and to examine its correlation with metabolism and immune infiltration. The proportion of parenchymal cells exhibiting high histidine metabolism was significantly increased, accompanied by a general reduction in immune and stromal cell infiltration. Notably, macrophages and T cells demonstrated impaired antitumor functions. In the high histidine metabolism group, multiple critical cell communication pathways (e.g., MIF, CLEC, MHC II) were downregulated, macrophages shifted toward immunosuppressive subpopulations, T cells exhibited an exhaustion phenotype, and CD8 + T-cell activation was diminished. Further in vivo and in vitro co-culture experiments confirmed that elevated histidine concentrations promoted M2 polarization in macrophages and weakened T-cell cytotoxicity, accelerating tumor proliferation. According to TCGA analyses, BUD23 was upregulated in the high histidine metabolism group and significantly negatively correlated with patient survival and immune cell infiltration. Silencing BUD23 boosted immune cell activation and cytotoxic effects, effectively reversing the immunosuppressive microenvironment. A multivariable Cox regression-based prognostic model indicated unfavorable outcomes in patients with high histidine metabolism. Histidine metabolism drives tumor cell metabolic reprogramming and reshapes the tumor immune microenvironment through intercellular communication, thereby promoting tumor progression. BUD23 shows promise as a biomarker for prognosis and immune response prediction in liver cancer. This study provides new therapeutic targets and theoretical support for liver cancer treatment by targeting histidine metabolism. |
| ArticleNumber | 262 |
| Audience | Academic |
| Author | Ma, Haiqing Huang, Fuxin Liu, Jiayao Sun, Huanhuan Lin, Peixu Xing, Fan Zhou, Pincheng Liu, Pengcheng Wang, Jie |
| Author_xml | – sequence: 1 givenname: Pengcheng surname: Liu fullname: Liu, Pengcheng – sequence: 2 givenname: Fuxin surname: Huang fullname: Huang, Fuxin – sequence: 3 givenname: Peixu surname: Lin fullname: Lin, Peixu – sequence: 4 givenname: Jiayao surname: Liu fullname: Liu, Jiayao – sequence: 5 givenname: Pincheng surname: Zhou fullname: Zhou, Pincheng – sequence: 6 givenname: Jie surname: Wang fullname: Wang, Jie – sequence: 7 givenname: Huanhuan surname: Sun fullname: Sun, Huanhuan – sequence: 8 givenname: Fan surname: Xing fullname: Xing, Fan – sequence: 9 givenname: Haiqing orcidid: 0000-0002-5524-6097 surname: Ma fullname: Ma, Haiqing |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/40038727$$D View this record in MEDLINE/PubMed |
| BookMark | eNptkkuLHCEURoswIfNI_kAWoSCbbGriq0pdhWHIPGAgm2QtlnWtdii1o1UNTf587O5JMw1BUNHjwcv9LquzEANU1UeMrjEW3deMiex4g0jboI6U3fZNdYEZl00reHf2an9eXeb8jBBhLZPvqnOGEBWc8Ivqz4PLsxtcgNrDrPs4uezrIbkN5Hoqc6qNDqYs6xTHBDm7GOqN07Xzftm9ciZFCBuXYvAQ5trHYZn0vMPmVYrLuDqaTZ1gr9HeuzC-r95aPWX48LJeVb_uvv-8fWieftw_3t48NYZhPjfUGNNpLIm0raZWyF5aq3tEMSaYMmJwj5hu25YJYWjfaltwoEIPgC2hiF5VjwfvEPWzWifnddqqqJ3aH8Q0Kp1mZyZQRA5YWim5ZpYBIQIYoI7xVkgYNOXF9e3gWi-9h8GUipOeTqSnN8Gt1Bg3qnSMc4FlMXx5MaT4e4E8K--ygWnSAeKSFcWcYYQw6Qr6-YCOuvzNBRuL0uxwdSNK70Xh2kJd_4cqY4DSnBIZ68r5yYNPr2s4fv5fKgpADkBpbc4J7BHBaFdIpw7RUyV6ah89taV_AasAzvM |
| Cites_doi | 10.1016/j.cmet.2022.01.007 10.1186/s12943-021-01316-8 10.1016/j.apsb.2021.09.019 10.1017/S0007114514001056 10.15252/embj.201899895 10.1080/2162402X.2017.1290034 10.1080/19490976.2024.2370616 10.1016/j.ccell.2021.11.002 10.1038/s41575-024-00967-4 10.1016/j.cell.2021.04.015 10.1016/j.ccell.2024.01.007 10.1016/j.cell.2023.09.011 10.1016/j.jaci.2011.06.051 10.1038/s41388-021-01950-y 10.1038/s41568-021-00378-6 10.3390/nu8070420 10.1038/s41572-020-00240-3 10.1186/s13046-020-01629-4 10.1002/hep.29898 10.1016/j.stem.2022.09.009 10.1186/s13045-024-01527-8 10.1186/s40001-023-01612-7 10.1016/j.cell.2016.05.041 10.1002/advs.202306929 10.1097/HEP.0000000000000005 10.1136/gutjnl-2020-323071 10.1038/s41577-019-0185-9 10.1038/s44318-024-00110-8 10.1007/s00125-013-2839-7 10.1007/s00018-023-04742-7 10.1093/jn/nxaa079 10.1016/j.jhep.2019.08.017 10.1017/S0007114511005289 10.3390/nu12030848 10.1016/j.ccell.2021.11.007 10.1016/j.jhepr.2022.100479 10.1016/j.foodchem.2021.129884 10.1016/j.cmet.2024.05.003 10.1016/j.pharmthera.2024.108722 10.1016/j.trecan.2021.01.012 10.1093/ajcn/87.6.1860 10.1111/all.12330 |
| ContentType | Journal Article |
| Copyright | 2025. The Author(s). COPYRIGHT 2025 BioMed Central Ltd. The Author(s) 2025 2025 |
| Copyright_xml | – notice: 2025. The Author(s). – notice: COPYRIGHT 2025 BioMed Central Ltd. – notice: The Author(s) 2025 2025 |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM DOA |
| DOI | 10.1186/s12967-025-06267-y |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1479-5876 |
| EndPage | 20 |
| ExternalDocumentID | oai_doaj_org_article_29d19f997a4f4e228e4e0647589eda37 PMC11877819 A829681005 40038727 10_1186_s12967_025_06267_y |
| Genre | Journal Article |
| GeographicLocations | United States |
| GeographicLocations_xml | – name: United States |
| GrantInformation_xml | – fundername: Natural Science Foundation of Guangdong Province grantid: 2021A1515010790 – fundername: Natural Science Foundation of Guangdong Province grantid: 2023A1515012872 – fundername: National Natural Science Foundation of China grantid: 82473318 – fundername: National Natural Science Foundation of China grantid: 82072719 |
| GroupedDBID | --- 0R~ 29L 2WC 53G 5VS 6PF 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAWTL AAYXX ABDBF ABUWG ACGFO ACGFS ACIHN ACIWK ACPRK ACUHS ADBBV ADUKV AEAQA AENEX AFKRA AFPKN AFRAH AHBYD AHMBA AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CITATION CS3 DIK DU5 E3Z EBD EBLON EBS ESX F5P FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO IHR INH INR ITC KQ8 M1P M~E O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO RBZ RNS ROL RPM RSV SBL SOJ TR2 TUS UKHRP WOQ WOW XSB ~8M CGR CUY CVF ECM EIF NPM PMFND 7X8 PPXIY 5PM PJZUB PUEGO |
| ID | FETCH-LOGICAL-c417t-3ccc6a1929f5a3f89b9ffab031121342c1b04a555488c3b5afc6ae38ade1f2303 |
| IEDL.DBID | DOA |
| ISSN | 1479-5876 |
| IngestDate | Wed Aug 27 01:21:10 EDT 2025 Thu Aug 21 18:27:16 EDT 2025 Fri Jul 11 00:18:18 EDT 2025 Tue Jun 17 21:59:26 EDT 2025 Tue Jun 10 20:59:39 EDT 2025 Mon May 12 02:38:53 EDT 2025 Tue Jul 01 05:26:09 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Immune suppression Hepatocellular carcinoma Histidine metabolism Prognosis BUD23 Tumor microenvironment |
| Language | English |
| License | 2025. The Author(s). Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c417t-3ccc6a1929f5a3f89b9ffab031121342c1b04a555488c3b5afc6ae38ade1f2303 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| ORCID | 0000-0002-5524-6097 |
| OpenAccessLink | https://doaj.org/article/29d19f997a4f4e228e4e0647589eda37 |
| PMID | 40038727 |
| PQID | 3174100126 |
| PQPubID | 23479 |
| PageCount | 20 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_29d19f997a4f4e228e4e0647589eda37 pubmedcentral_primary_oai_pubmedcentral_nih_gov_11877819 proquest_miscellaneous_3174100126 gale_infotracmisc_A829681005 gale_infotracacademiconefile_A829681005 pubmed_primary_40038727 crossref_primary_10_1186_s12967_025_06267_y |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2025-03-04 |
| PublicationDateYYYYMMDD | 2025-03-04 |
| PublicationDate_xml | – month: 03 year: 2025 text: 2025-03-04 day: 04 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: London |
| PublicationTitle | Journal of translational medicine |
| PublicationTitleAlternate | J Transl Med |
| PublicationYear | 2025 |
| Publisher | BioMed Central Ltd BioMed Central BMC |
| Publisher_xml | – name: BioMed Central Ltd – name: BioMed Central – name: BMC |
| References | I Martinez-Reyes (6267_CR38) 2021; 21 X Sun (6267_CR24) 2014; 112 A Agus (6267_CR1) 2021; 70 YC Niu (6267_CR27) 2012; 108 NN Pavlova (6267_CR42) 2022; 34 J Lin (6267_CR16) 2024; 17 X Chen (6267_CR35) 2017; 6 V Leone (6267_CR30) 2021; 7 Z Huang (6267_CR32) 2024; 11 L O’Mahony (6267_CR9) 2011; 128 Y Wang (6267_CR40) 2024; 43 H Li (6267_CR12) 2022; 40 D Du (6267_CR21) 2022; 12 M Watanabe (6267_CR26) 2008; 87 MK Brahma (6267_CR31) 2021; 40 S Smolinska (6267_CR11) 2014; 69 JM Llovet (6267_CR4) 2021; 7 NN Pavlova (6267_CR39) 2016; 23 L Xia (6267_CR37) 2021; 20 E Tiligada (6267_CR10) 2024; 263 P Horn (6267_CR15) 2024; 36 J Chen (6267_CR13) 2022; 29 A Koh (6267_CR23) 2016; 165 L Yan-Chuan (6267_CR25) 2016; 8 MV Warmbrunn (6267_CR43) 2024; 16 S Chen (6267_CR14) 2022; 40 Y Jiao (6267_CR36) 2023; 80 6267_CR5 J Feng (6267_CR18) 2020; 39 S Rebouissou (6267_CR29) 2020; 72 F Yang (6267_CR17) 2023; 78 6267_CR2 R Loomba (6267_CR19) 2021; 184 B Paul (6267_CR20) 2022; 4 ME Brosnan (6267_CR7) 2020; 150 D Mossmann (6267_CR41) 2023; 186 PI Johansson (6267_CR3) 2024; 29 X Yang (6267_CR6) 2024; 42 JJ Bernard (6267_CR22) 2019; 19 RN Feng (6267_CR28) 2013; 56 L Kennedy (6267_CR34) 2018; 68 R Ghassem Zadeh (6267_CR8) 2021; 358 F Froldi (6267_CR33) 2019; 38 |
| References_xml | – volume: 34 start-page: 355 issue: 3 year: 2022 ident: 6267_CR42 publication-title: Cell Metab doi: 10.1016/j.cmet.2022.01.007 – volume: 20 start-page: 28 issue: 1 year: 2021 ident: 6267_CR37 publication-title: Mol Cancer doi: 10.1186/s12943-021-01316-8 – volume: 12 start-page: 558 issue: 2 year: 2022 ident: 6267_CR21 publication-title: Acta Pharm Sin B doi: 10.1016/j.apsb.2021.09.019 – volume: 112 start-page: 477 issue: 4 year: 2014 ident: 6267_CR24 publication-title: Br J Nutr doi: 10.1017/S0007114514001056 – volume: 38 start-page: e99895 issue: 7 year: 2019 ident: 6267_CR33 publication-title: EMBO J doi: 10.15252/embj.201899895 – volume: 6 start-page: e1290034 issue: 3 year: 2017 ident: 6267_CR35 publication-title: Oncoimmunology doi: 10.1080/2162402X.2017.1290034 – volume: 16 start-page: 2370616 issue: 1 year: 2024 ident: 6267_CR43 publication-title: Gut Microbes doi: 10.1080/19490976.2024.2370616 – volume: 40 start-page: 36 issue: 1 year: 2022 ident: 6267_CR12 publication-title: Cancer Cell doi: 10.1016/j.ccell.2021.11.002 – ident: 6267_CR5 doi: 10.1038/s41575-024-00967-4 – volume: 184 start-page: 2537 issue: 10 year: 2021 ident: 6267_CR19 publication-title: Cell doi: 10.1016/j.cell.2021.04.015 – volume: 42 start-page: 180 issue: 2 year: 2024 ident: 6267_CR6 publication-title: Cancer Cell doi: 10.1016/j.ccell.2024.01.007 – volume: 186 start-page: 5068 issue: 23 year: 2023 ident: 6267_CR41 publication-title: Cell doi: 10.1016/j.cell.2023.09.011 – volume: 128 start-page: 1153 issue: 6 year: 2011 ident: 6267_CR9 publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2011.06.051 – volume: 40 start-page: 5155 issue: 33 year: 2021 ident: 6267_CR31 publication-title: Oncogene doi: 10.1038/s41388-021-01950-y – volume: 21 start-page: 669 issue: 10 year: 2021 ident: 6267_CR38 publication-title: Nat Rev Cancer doi: 10.1038/s41568-021-00378-6 – volume: 8 start-page: 420 issue: 7 year: 2016 ident: 6267_CR25 publication-title: Nutrients doi: 10.3390/nu8070420 – volume: 7 start-page: 6 issue: 1 year: 2021 ident: 6267_CR4 publication-title: Nat Rev Dis Primers doi: 10.1038/s41572-020-00240-3 – volume: 39 start-page: 126 issue: 1 year: 2020 ident: 6267_CR18 publication-title: J Exp Clin Cancer Res doi: 10.1186/s13046-020-01629-4 – volume: 68 start-page: 1042 issue: 3 year: 2018 ident: 6267_CR34 publication-title: Hepatology doi: 10.1002/hep.29898 – volume: 29 start-page: 1531 issue: 11 year: 2022 ident: 6267_CR13 publication-title: Cell Stem Cell doi: 10.1016/j.stem.2022.09.009 – volume: 17 start-page: 6 issue: 1 year: 2024 ident: 6267_CR16 publication-title: J Hematol Oncol doi: 10.1186/s13045-024-01527-8 – volume: 29 start-page: 71 issue: 1 year: 2024 ident: 6267_CR3 publication-title: Eur J Med Res doi: 10.1186/s40001-023-01612-7 – volume: 165 start-page: 1332 issue: 6 year: 2016 ident: 6267_CR23 publication-title: Cell doi: 10.1016/j.cell.2016.05.041 – volume: 11 start-page: e2306929 issue: 13 year: 2024 ident: 6267_CR32 publication-title: Adv Sci (Weinh) doi: 10.1002/advs.202306929 – volume: 78 start-page: 1602 issue: 5 year: 2023 ident: 6267_CR17 publication-title: Hepatology doi: 10.1097/HEP.0000000000000005 – volume: 70 start-page: 1174 issue: 6 year: 2021 ident: 6267_CR1 publication-title: Gut doi: 10.1136/gutjnl-2020-323071 – volume: 19 start-page: 688 issue: 11 year: 2019 ident: 6267_CR22 publication-title: Nat Rev Immunol doi: 10.1038/s41577-019-0185-9 – volume: 23 start-page: 27 issue: 1 year: 2016 ident: 6267_CR39 publication-title: Emerg Hallm Cancer Metabolism Cell Metab – volume: 43 start-page: 2368 issue: 12 year: 2024 ident: 6267_CR40 publication-title: EMBO J doi: 10.1038/s44318-024-00110-8 – volume: 56 start-page: 985 issue: 5 year: 2013 ident: 6267_CR28 publication-title: Diabetologia doi: 10.1007/s00125-013-2839-7 – volume: 80 start-page: 119 issue: 5 year: 2023 ident: 6267_CR36 publication-title: Cell Mol Life Sci doi: 10.1007/s00018-023-04742-7 – volume: 150 start-page: S2570 issue: Suppl 1 year: 2020 ident: 6267_CR7 publication-title: J Nutr doi: 10.1093/jn/nxaa079 – volume: 72 start-page: 215 issue: 2 year: 2020 ident: 6267_CR29 publication-title: J Hepatol doi: 10.1016/j.jhep.2019.08.017 – volume: 108 start-page: 57 issue: 1 year: 2012 ident: 6267_CR27 publication-title: Br J Nutr doi: 10.1017/S0007114511005289 – ident: 6267_CR2 doi: 10.3390/nu12030848 – volume: 40 start-page: 9 issue: 1 year: 2022 ident: 6267_CR14 publication-title: Cancer Cell doi: 10.1016/j.ccell.2021.11.007 – volume: 4 start-page: 100479 issue: 6 year: 2022 ident: 6267_CR20 publication-title: JHEP Rep doi: 10.1016/j.jhepr.2022.100479 – volume: 358 start-page: 129884 year: 2021 ident: 6267_CR8 publication-title: Food Chem doi: 10.1016/j.foodchem.2021.129884 – volume: 36 start-page: 1439 issue: 7 year: 2024 ident: 6267_CR15 publication-title: Cell Metab doi: 10.1016/j.cmet.2024.05.003 – volume: 263 start-page: 108722 year: 2024 ident: 6267_CR10 publication-title: Pharmacol Ther doi: 10.1016/j.pharmthera.2024.108722 – volume: 7 start-page: 606 issue: 7 year: 2021 ident: 6267_CR30 publication-title: Trends Cancer doi: 10.1016/j.trecan.2021.01.012 – volume: 87 start-page: 1860 issue: 6 year: 2008 ident: 6267_CR26 publication-title: Am J Clin Nutr doi: 10.1093/ajcn/87.6.1860 – volume: 69 start-page: 273 issue: 3 year: 2014 ident: 6267_CR11 publication-title: Allergy doi: 10.1111/all.12330 |
| SSID | ssj0024549 |
| Score | 2.4420898 |
| Snippet | Histidine metabolism is crucial in role in tumor biology, contributing to tumor progression, immune regulation, and metabolic reprogramming. In hepatocellular... Background Histidine metabolism is crucial in role in tumor biology, contributing to tumor progression, immune regulation, and metabolic reprogramming. In... Abstract Background Histidine metabolism is crucial in role in tumor biology, contributing to tumor progression, immune regulation, and metabolic... |
| SourceID | doaj pubmedcentral proquest gale pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database |
| StartPage | 262 |
| SubjectTerms | Amino acid metabolism Animals B cells BUD23 Cancer Carcinoma, Hepatocellular - genetics Carcinoma, Hepatocellular - immunology Carcinoma, Hepatocellular - metabolism Carcinoma, Hepatocellular - pathology Cell Line, Tumor Cell Proliferation Cellular Reprogramming Development and progression Disease Progression Female Gene Expression Regulation, Neoplastic Genes Genetic aspects Health aspects Hepatocellular carcinoma Histidine Histidine - metabolism Humans Immune response Immune suppression Immune system Immunotherapy Liver cancer Liver Neoplasms - genetics Liver Neoplasms - immunology Liver Neoplasms - metabolism Liver Neoplasms - pathology Macrophages Macrophages - metabolism Male Metabolic Reprogramming Mice Oncology, Experimental Prognosis RNA RNA sequencing T cells Tumor microenvironment Tumor Microenvironment - immunology |
| Title | Histidine metabolism drives liver cancer progression via immune microenvironment modulation through metabolic reprogramming |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/40038727 https://www.proquest.com/docview/3174100126 https://pubmed.ncbi.nlm.nih.gov/PMC11877819 https://doaj.org/article/29d19f997a4f4e228e4e0647589eda37 |
| Volume | 23 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Na9wwEBVtCqWX0u-4TRcVCj0UE1uWLOmYLQmh0FBCA0svQpIlash6y-4mEPLnOyPby5oeeunFB0u2Zb2RZgbNvCHkI_NCqIqznDuhwUFxPLdVrPPIgmaysXhiiNEWF_X5Ff-6EIu9Ul8YE9bTA_cTd8x0U-qotbQ88sCYCjxggqRQOjS2SnnkoPNGZ2pk2QO3Z0yRUfXxBrQabAhYurUAC17mdxM1lNj6_96T95TSNGByTwOdPSNPB9ORnvRDfk4ehO4FefxtOBx_Se6R8qMFXRToMmwB3Ot2s6TNGoll6TXGX1CPGK9pCsrqCTnobWtpi0ki8BQG5-1lvtHlqhmqe9Ghns_uzZ4iHWaK7VqC9ntFrs5Of3w5z4faCrnnpdzmlfe-tmDe6SgAHKWdjtE6WOKJ44350hXcCjA2lPKVEzZC91Ap24QygttSvSYH3aoLh4TG2gcrSye58tw3hbWS-0IAOs4VQoSMfB6n2vzuKTRMcj1UbXpgDABjEjDmLiNzRGPXE-mv0w0QCjMIhfmXUGTkE2JpcJECYN4OuQYwYKS7MicKPqtK2IEycjTpCYvLT5o_jNJgsAkj0rqwutkYsLs48lexOiNveunYjZnjeSsYhhlRE7mZ_NS0pWt_JW5vrP4uwUp7-z-m4R15wpLMV3nBj8jBdn0T3oMNtXUz8lAu5Iw8mp9efL-cpcUD18v5zz8gBCBM |
| linkProvider | Directory of Open Access Journals |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Histidine+metabolism+drives+liver+cancer+progression+via+immune+microenvironment+modulation+through+metabolic+reprogramming&rft.jtitle=Journal+of+translational+medicine&rft.au=Liu%2C+Pengcheng&rft.au=Huang%2C+Fuxin&rft.au=Lin%2C+Peixu&rft.au=Liu%2C+Jiayao&rft.date=2025-03-04&rft.pub=BioMed+Central+Ltd&rft.issn=1479-5876&rft.eissn=1479-5876&rft.volume=23&rft.issue=1&rft_id=info:doi/10.1186%2Fs12967-025-06267-y&rft.externalDocID=A829681005 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1479-5876&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1479-5876&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1479-5876&client=summon |